Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A neoplasm with neuroendocrine differentiation that arises from the prostate gland. This category includes carcinoid tumors and small cell carcinomas.
Biomarker and diagnostic research for prostate neuroendocrine neoplasm has been reported in the published literature.
1 clinical trial registered. Interventions under study include drug therapy and biologic therapy. Pipeline includes 1 PHASE1. Research is primarily sponsored by academic and government institutions.
213 publications have been identified in PubMed for prostate neuroendocrine neoplasm. Kisho has analyzed 154 by research type. Research spans Basic Science / Preclinical (47%), Review / Meta-Analysis (31%), and Diagnostic / Biomarker (8%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 73 |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 2:56 PM UTC
Research summaries | 48 | 31% |
Testing and diagnosis research | 12 | 8% |
New treatment approaches | 8 | 5% |
Clinical study results | 5 | 3% |
Disease patterns and progression | 5 | 3% |
Other research | 2 | 1% |
Patient case studies | 1 | 1% |
Ku SY (2026). [PMID: 41041866](https://pubmed.ncbi.nlm.nih.gov/41041866/). *Mol Cancer Ther*. [Basic Science / Preclinical]
Wu T (2026). [PMID: 42126948](https://pubmed.ncbi.nlm.nih.gov/42126948/). *Cell Rep*. [Basic Science / Preclinical]
Tosun I (2026). [PMID: 41547728](https://pubmed.ncbi.nlm.nih.gov/41547728/). *BMC Urol*. [Basic Science / Preclinical]
Chen YW (2026). [PMID: 41785440](https://pubmed.ncbi.nlm.nih.gov/41785440/). *JCO Precis Oncol*. [Basic Science / Preclinical]
Tendler S (2026). [PMID: 41628333](https://pubmed.ncbi.nlm.nih.gov/41628333/). *Proc Natl Acad Sci U S A*. [Gene Therapy / Novel Therapeutics]
Shimomura T (2026). [PMID: 41995698](https://pubmed.ncbi.nlm.nih.gov/41995698/). *Prostate*. [Diagnostic / Biomarker]
Mak CSL (2026). [PMID: 41319861](https://pubmed.ncbi.nlm.nih.gov/41319861/). *Cancer letters*. [Diagnostic / Biomarker]
Singh R (2026). [PMID: 41720768](https://pubmed.ncbi.nlm.nih.gov/41720768/). *Nature communications*. [Basic Science / Preclinical]
McKay RR (2026). [PMID: 41817312](https://pubmed.ncbi.nlm.nih.gov/41817312/). *Clin Cancer Res*. [Basic Science / Preclinical]
Li T (2026). [PMID: 41162153](https://pubmed.ncbi.nlm.nih.gov/41162153/). *Genes & development*. [Basic Science / Preclinical]
AI-curated news mentioning prostate neuroendocrine neoplasm
Updated Aug 7, 2026
A case report details the successful management of urethral metastasis in therapy-induced neuroendocrine prostate cancer using chemoradiotherapy. This highlights potential treatment strategies for a challenging manifestation of prostate cancer.
A recent case report highlights the genetic diagnosis of macrotia in patients with PIK3CA-Related Overgrowth Spectrum (PROS) and discusses the long-term outcomes of otoplasty. This study contributes to the understanding of genetic factors in PROS and the effectiveness of surgical interventions.